AstraZeneca PLC (AZN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic advancements.
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.
AstraZeneca PLC (NASDAQ:AZN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, expectations were $1.07. Pascal Soriot: Thank you, Andy. Welcome everybody.
Centrus Energy Corp. (LEU) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ETCompany ParticipantsNeal Nagarajan - Head, IRAmir Vexler
Proto Labs (PRLB) Q4 2024 Earnings Call Transcript
Operator Greetings, and welcome to the Proto Labs fourth quarter and fiscal year 2024 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.
Omega Healthcare Investors (OHI) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Feb 06, 2025, 10:00 a.m. ET Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Omega Healthcare Investors fourth quarter earnings conference call.
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Q4 and Fiscal Year 2024 Earnings Call. [Operator Instructions] Please note today's call will be recorded, and I will be standing by should you need any assistance.
AstraZeneca’s Full Year and Q4 2024 results
Second interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Di ...
AstraZeneca gains as Q4 results clear China overhang
AstraZeneca (AZN) stock rises as its Q4 results which exceeded Street forecasts address concerns over its China investigation ...
Pharmaceutical Technology on MSN19h
AstraZeneca’s shares rise as it addresses China investigation
In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...
Why AstraZeneca Topped the Market on Thursday
AstraZeneca unveiled both its fourth-quarter and full-year 2024 results before market open today, revealing that its total revenue was $14.89 billion. This represented a meaty 24% improvement over Q4 ...
BioSpace1d
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
AstraZeneca reports Q4 core EPS $2.09, up 49% at CER
Reports Q4 reported EPS 97c vs. 62c last year. Reports Q4 revenue $14.89B, consensus $14.28B. Pascal Soriot, CEO, AstraZeneca (AZN), ...
precisionmedicineonline20h
AstraZeneca Optimistic About Phase III Capivasertib Data in 2025, Reports Strong Q4 Product Growth
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.